目的:1型糖尿病(T1DM)代谢改变损害血管舒张功能,这导致组织缺氧和微血管病变。高压氧治疗(HBOT)能显著改善T1DM患者的缺血状况,减少血管并发症。我们研究的目的是评估HBOT对血浆脂肪酸(FA)组成的影响,胰岛素样生长因子结合蛋白1(IGFBP-1)在1型糖尿病患者中的表达。
方法:我们的研究包括24名诊断为外周血管并发症的成人T1DM患者。患者在2.4绝对大气压下暴露于10次100%氧气吸入1小时。入院时和HBOT后收集血液样本用于测量代谢参数,FA组成和IGFBP-1。血浆FA组成的测量通过气相色谱法测定。通过Western印迹分析估计血清中IGFBP-1的表达。
结果:HBOT降低了血液中总胆固醇水平(p<0.05),甘油三酯(p<0.05)和低密度脂蛋白(p<0.05)。HBOT增加了单个FAs:棕榈酸的血浆水平(p<0.05),棕榈油酸(p<0.05),二十二碳五烯酸(p<0.05)和二十二碳六烯酸(p<0.01),硬脂酸含量降低(p<0.05),α亚麻酸(p<0.05)和亚油酸(p<0.01)。IGFBP-1的表达增加(p<0.01),而HBOT后血清胰岛素水平(p<0.001)下降。
结论:我们的结果表明,HBOT通过改善血脂和改变FA组成在T1DM患者中发挥有益作用。
OBJECTIVE: Metabolic changes in type 1 diabetes mellitus (T1DM) impair vasodilation, and this leads to tissue hypoxia and microvascular pathology. Hyperbaric oxygen therapy (HBOT) can significantly improve the outcome of ischemic conditions in T1DM patients and reduce vascular complications. The aim of our study was to assess the effects of HBOT on plasma fatty acid (FA) composition, and expression of insulin-like growth factor binding protein 1 (IGFBP-1) in T1DM patients.
METHODS: Our study included 24 adult T1DM patients diagnosed with peripheral vascular complications. The patients were exposed to 10 sessions of 100% oxygen inhalation at 2.4 atmosphere absolute for 1 hour. Blood samples were collected at admission and after HBOT for measurement of metabolic parameters, FA composition and IGFBP-1. Measurement of plasma FA composition was determined by gas chromatography. Expression of IGFBP-1 in the serum was estimated by Western blot analysis.
RESULTS: HBOT decreased blood levels of total cholesterol (p<0.05), triglycerides (p<0.05) and low-density lipoprotein (p<0.05). HBOT increased plasma levels of individual FAs: palmitic acid (p<0.05), palmitoleic acid (p<0.05), docosapentaenoic acid (p<0.05) and docosahexaenoic acid (p<0.01), and decreased levels of stearic acid (p<0.05), alpha linolenic acid (p<0.05) and linoleic acid (p<0.01). Expression of IGFBP-1 (p<0.01) was increased, whereas the level of insulin (p<0.001) was decreased in the serum after HBOT.
CONCLUSIONS: Our results indicate that HBOT exerts beneficial effects in T1DM patients by improving the lipid profile and altering FA composition.